Drugs List

Therapeutic Indications

Uses

Vitamin B deficiency
Vitamin B deficiency - prophylaxis

Contraindications

Hereditary fructose intolerance

Precautions and Warnings

Contains hydroxybenzoate
Contains propylene glycol: may cause irritation
Presentations with sorbitol unsuitable in hereditary fructose intolerance

Pregnancy and Lactation

Pregnancy

The manufacturer states that the product is considered safe in the recommended dose.

The five ingredients are water-soluble B-complex vitamins and are essential for various metabolic processes. There are recommended daily allowances for vitamin B components during pregnancy, and supplementation may be recommended if the mother is deficient.

The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Lactation

The manufacturer states that the product is considered safe in the recommended dose.

The five ingredients are water-soluble B-complex vitamins and are essential for various metabolic processes. There are recommended daily allowances for vitamin B components during pregnancy, and supplementation may be recommended if the mother is deficient.

In high doses, pyridoxine may interfere with prolactin release and should only be used with caution in nursing mothers.

Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1

Side Effects

None Known

Presentation

Oral solution containing thiamine hydrochloride, riboflavin sodium phosphate, nicotinamide, pyridoxine hydrochloride and dexpanthenol

Drugs List

Therapeutic Indications

Uses

Vitamin B deficiency
Vitamin B deficiency - prophylaxis

Dosage

Adults

Elderly

Children

Adolescents

Contraindications

Hereditary fructose intolerance

Precautions and Warnings

Contains hydroxybenzoate
Contains propylene glycol: may cause irritation
Presentations with sorbitol unsuitable in hereditary fructose intolerance

Pregnancy and Lactation

Pregnancy

The manufacturer states that the product is considered safe in the recommended dose.

The five ingredients are water-soluble B-complex vitamins and are essential for various metabolic processes. There are recommended daily allowances for vitamin B components during pregnancy, and supplementation may be recommended if the mother is deficient.

The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Lactation

The manufacturer states that the product is considered safe in the recommended dose.

The five ingredients are water-soluble B-complex vitamins and are essential for various metabolic processes. There are recommended daily allowances for vitamin B components during pregnancy, and supplementation may be recommended if the mother is deficient.

In high doses, pyridoxine may interfere with prolactin release and should only be used with caution in nursing mothers.

Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1

Side Effects

None Known

Overdosage

It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

The following number will direct the caller to the relevant local centre (0844) 892 0111

Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Further Information

Last Full Review Date: July 2015.

Reference Sources

Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.

Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. Accessed on 20 July 2015.

Summary of Product Characteristics: Vigranon-B syrup. Wallace Manufacturing Chemists Ltd. Revised December 2014.

UK Drugs in Lactation Advisory Service.
Available at: https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1
Last accessed: 5 June 2015